Uniunea Europeană - română - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - risankizumab - psoriasis; arthritis, psoriatic - imunosupresoare - plaque psoriasisskyrizi is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. psoriatic arthritisskyrizi, alone or in combination with methotrexate (mtx), is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (dmards). crohn's diseaseskyrizi is indicated for the treatment of adult patients with moderately to severely active crohn's disease who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biologic therapy.

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

abbvie s.r.l. - italia - risankizumabum - sol. inj. in seringa preumpluta - 75mg/0,83ml - imunosupresoare inhibitori de interleukina

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

abbvie s.r.l. - italia - risankizumabum - sol. inj. in seringa preumpluta - 150mg/1ml - imunosupresoare inhibitori de interleukina

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

abbvie s.r.l. - italia - risankizumabum - sol. inj. in stilou injector preumplut - 150mg/1ml - imunosupresoare inhibitori de interleukina

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

abbvie deutschland gmbh & co. kg - germania - risankizumabum - sol inj. in cartus - 150 mg/ml - imunosupresoare inhibitori de interleukina

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

abbvie s.r.l. - italia - risankizumabum - conc. pt. sol. perf. - 60 mg/ml - imunosupresoare inhibitori de interleukina

Uniunea Europeană - română - EMA (European Medicines Agency)

boehringer ingelheim international gmbh - spesolimab - psoriazis - imunosupresoare - spevigo is indicated for the treatment of flares in adult patients with generalised pustular psoriasis (gpp) as monotherapy.

Uniunea Europeană - română - EMA (European Medicines Agency)

novartis europharm limited - crizanlizumab - anemie, sickle cell - other hematological agents - adakveo is indicated for the prevention of recurrent vaso occlusive crises (vocs) in sickle cell disease patients aged 16 years and older. it can be given as an add on therapy to hydroxyurea/hydroxycarbamide (hu/hc) or as monotherapy in patients for whom hu/hc is inappropriate or inadequate.

Uniunea Europeană - română - EMA (European Medicines Agency)

samsung bioepis nl b.v. - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; myopia, degenerative - oftalmologice - byooviz is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).

Uniunea Europeană - română - EMA (European Medicines Agency)

stada arzneimittel ag - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - oftalmologice - ximluci is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).